
    the study was terminated early for business reasons, and not due to concerns regarding safety
    or lack of efficacy.
  
['cutaneous t-cell lymphoma/mycosis fungoides']
['cobomarsen', 'vorinostat']

        Key Inclusion Criteria:

          -  Biopsy-proven CTCL, MF subtype

          -  Clinical stage IB, II, or III, with staging based on screening assessments

          -  Minimum mSWAT score of 10 at screening

          -  Receipt of at least one prior therapy for CTCL

        Key Exclusion Criteria:

          -  Previous enrollment in a cobomarsen study

          -  Prior therapy with vorinostat or other HDAC inhibitors, or contraindication to an HDAC
             inhibitor

          -  Sézary syndrome or mycosis fungoides with B2 involvement, defined as documented
             history of B2 and/or B2 staging at screening

          -  Evidence of large cell transformation

          -  Lymph node involvement at screening, unless radiologically or histologically confirmed
             to be nonmalignant

          -  Visceral involvement related to MF at screening
      